Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera. 1995

X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Japan.

We investigated the murine antibody response to recombinant p17 (rp17) of human immunodeficiency virus type 1 (HIV-1) and the human antibody response directed to p17 in HIV-1 infection. Three large peptides covering residues 12-29, 53-87 and 87-115 of p17 were synthesized. The cysteine residues 57 and 87 of peptide 53-87 were reoxidized to form a disulfide bridge. Eighteen out of 19 murine monoclonal anti-rp17 antibodies had relatively high affinities (KA = 1.9 x 10(5)-1.4 x 10(8) M-1) with one of the 3 p17 peptides in the liquid phase. Each monoclonal antibody reacted only with one particular peptide and had no reactivity with the other 2 p17 peptides. All the monoclonal antibodies reacted with rp17 in the liquid phase with a reasonable degree of affinity (KA = 2.0 x 10(5)-1.8 x 10(7) M-1). Four HIV-1 carrier sera, which were positive in ELISA using rp17 as the antigen, reacted positively in an ELISA using 3 p17 peptides which were used to titrate murine monoclonal antibodies. Murine monoclonal antibodies having specificity for the 3 p17 peptides stained live HIV-1-infected cells by means of indirect membrane immunofluorescence, irrespective of their specificity. This suggests that the various portions of p17 (at least 3 regions of p17) were exposed on the surface of live infected cells, probably as short polypeptide chains.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001666 Binding Sites, Antibody Local surface sites on antibodies which react with antigen determinant sites on antigens (EPITOPES.) They are formed from parts of the variable regions of FAB FRAGMENTS. Antibody Binding Sites,Paratopes,Antibody Binding Site,Binding Site, Antibody,Paratope
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated

Related Publications

X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
January 1997, Revista do Instituto de Medicina Tropical de Sao Paulo,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
January 2004, AIDS research and human retroviruses,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
January 1989, Journal of virology,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
September 1995, AIDS research and human retroviruses,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
April 1990, Journal of immunological methods,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
September 1988, Proceedings of the National Academy of Sciences of the United States of America,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
April 1991, Clinical immunology and immunopathology,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
April 1992, The Journal of general virology,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
November 1987, Immunology letters,
X Liu, and A Ota, and M Watanabe, and S Ueda, and A Saitoh, and H Shinagawa, and A Nakata, and T Kurimura, and X Wang, and Y Zhao
November 1994, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!